Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Sponsor: Rhythm Pharmaceuticals, Inc.
Summary
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how well setmelanotide works and how safe it is, patients with cHO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 26 weeks on a therapeutic regimen.
Official title: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity
Key Details
Gender
All
Age Range
4 Years - Any
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2025-09-23
Completion Date
2028-03-13
Last Updated
2026-02-12
Healthy Volunteers
No
Conditions
Interventions
Setmelanotide
Solution for daily subcutaneous injection
Placebo
Placebo matched to setmelanotide for daily subcutaneous injection
Locations (11)
University of Alabama
Birmingham, Alabama, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Lurie Children's Hospital
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Children's Minnesota
Saint Paul, Minnesota, United States
Columbia University Irving Medical Center
New York, New York, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Seattle Children's Research Institute
Seattle, Washington, United States
UCL Great Ormond Street Institute of Child Health
London, Greater London, United Kingdom
Birmingham Women and Children's Hospital NHS Trust
Birmingham, West Midlands, United Kingdom
Hull Royal Infirmary
Hull, United Kingdom